Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Muscle Invasive Bladder cancer- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
"Muscle Invasive Bladder cancer- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Invasive Bladder cancer pipeline landscape is provided which includes the disease overview and Muscle Invasive Bladder cancer treatment guidelines.
The assessment part of the report embraces, in depth Muscle Invasive Bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Invasive Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Muscle Invasive Bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Muscle Invasive Bladder cancer.
Muscle Invasive Bladder cancer Emerging Drugs Chapters
This segment of the Muscle Invasive Bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscle Invasive Bladder cancer Emerging Drugs
TAR-200 : Janssen Research & Development, LLC
TAR-200 is a novel investigational small molecule targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4. Currently, the drug is in Phase III stage of its development for the treatment of Muscle Invasive Bladder Cancer.
AU-011: Aura Biosciences
AU-011 is a first-in-class targeted therapy in development for the muscle Invasive Bladder Cancer and noninvasive muscle bladder cancer. The drug candidate is being developed by Aura Biosciences. The drug is death stimulants and photosensitisers and also works as reactive oxygen species stimulants thus having mechanism of action. Currently, the drug is in Phase I stage of its development for the treatment of Muscle Invasive Bladder Cancer.
Muscle Invasive Bladder cancer: Therapeutic Assessment
Key Questions
- How many companies are developing Muscle Invasive Bladder cancer drugs?
- How many Muscle Invasive Bladder cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscle Invasive Bladder cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Muscle Invasive Bladder cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Muscle Invasive Bladder cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Aura Biosciences
- Janssen Research & Development, LLC
- Asieris Pharmaceuticals.
- RemeGen Co., Ltd.
Key Products
- TAR-200
- AU-011
- APL-1202
- RC48-ADC
Major Players in Muscle Invasive Bladder cancer
There are approx. 10+ key companies which are developing the therapies for Muscle Invasive Bladder cancer. The companies which have their Muscle Invasive Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, Janssen Research & Development, LLC.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Muscle Invasive Bladder cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle Invasive Bladder cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
Muscle Invasive Bladder cancer Report Insights
- Muscle Invasive Bladder cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Muscle Invasive Bladder cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/n6lnrk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
